» Articles » PMID: 12738038

Tetrandrine-induced Cell Cycle Arrest and Apoptosis in Hep G2 Cells

Overview
Journal Life Sci
Publisher Elsevier
Date 2003 May 10
PMID 12738038
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of tetrandrine in the human hepatoblastoma G2 (Hep G2) cell line were investigated in this study. The results showed that tetrandrine not only inhibited Hep G2 growth but also induced apoptosis and blocked cell cycle progression in the G1 phase. ELISA assay demonstrated that tetrandrine significantly increased the expression of p53 and p21/WAF1 protein, which caused cell cycle arrest. An enhancement in Fas/APO-1 and its two form ligands, membrane-bound Fas ligand (mFasL) and soluble Fas ligand (sFasL), might be responsible for the apoptotic effect induced by tetrandrine. Taken together, p53 and Fas/FasL apoptotic system possibly participated in the antiproliferative activity of tetrandrine in Hep G2 cells.

Citing Articles

Tetrandrine induces cell cycle arrest in cutaneous melanoma cells by inhibiting IL-6/CDC42 signaling.

Niu L, Chang J, Liu S, Shen J, Li X, Guo Y Arch Dermatol Res. 2025; 317(1):442.

PMID: 39976634 DOI: 10.1007/s00403-025-03930-8.


Insights on exploring the therapeutic potential and structural modification of Tetrandrine.

Gong L, Liu H, Xu B, Yu T, Wang Y, Niu S Future Med Chem. 2024; 16(24):2687-2700.

PMID: 39606807 PMC: 11731063. DOI: 10.1080/17568919.2024.2432297.


Tetrandrine for Targeting Therapy Resistance in Cancer.

Lima E, Lamichhane S, Bahadur K, Ferreira E, Koul S, Koul H Curr Top Med Chem. 2024; 24(12):1035-1049.

PMID: 38445699 PMC: 11259026. DOI: 10.2174/0115680266282360240222062032.


Phyto-therapeutics as anti-cancer agents in breast cancer: Pathway targeting and mechanistic elucidation.

Almilaibary A Saudi J Biol Sci. 2024; 31(3):103935.

PMID: 38327657 PMC: 10847379. DOI: 10.1016/j.sjbs.2024.103935.


Exploring the recent trends in perturbing the cellular signaling pathways in cancer by natural products.

Rahman M, Sarker M, Tumpa M, Yamin M, Islam T, Park M Front Pharmacol. 2022; 13:950109.

PMID: 36160435 PMC: 9498834. DOI: 10.3389/fphar.2022.950109.